VC
Value Add VC
⚡HomePulse⚡Helpful Apps📝Blog🤝Partner
← Pulse/Companies

Braveheart Bio on Pulse

Biotech

The full thread of our Braveheart Bio coverage — a running record of every development we've tracked, with the VC take on each.

2
Stories
2
With a headline figure
Jul 14, 2026
Since

Coverage Timeline

newest first
  1. Aug 5, 2026IPOBraveheart Bio Prices $300M IPO for Heart Drug$300M IPO→
  2. Jul 14, 2026IPOTwo New Biotech IPO Filings Land in One Week2 S-1s, same week→

All Coverage

IPO· Aug 5, 2026

Braveheart Bio Prices $300M IPO for Heart Drug

Illustration for: Braveheart Bio Prices $300M IPO for Heart Drug
IPO$300M IPO

Braveheart Bio Prices $300M IPO for Heart Drug

Braveheart Bio priced 18.75M shares at $16 to raise $300M on Nasdaq, funding its lead drug BHB-1893 for hypertrophic cardiomyopathy in the same week two other biotechs also priced.

Aug 5, 2026
IPO· Jul 14, 2026

Two New Biotech IPO Filings Land in One Week

Illustration for: Two New Biotech IPO Filings Land in One Week
IPO2 S-1s, same week

Two New Biotech IPO Filings Land in One Week

Braveheart Bio and Attovia Therapeutics both filed S-1s the same week, adding two names to 2026's biotech IPO pipeline amid the strongest H1 biotech venture funding since 2022.

Jul 14, 2026
@Trace_Cohen·t@nyvp.com